Buscar
Congreso SOLACI

Búsqueda de: lotus

Si no está conforme con los resultados, inténtelo de nuevamente.
Valvular Aortic Valve

Boston Scientific Discontinues Lotus Valve and Makes a New Bet

Mechanically-expanding valve Lotus Edge was discontinued worldwide, as recently informed by its manufacturer, Boston Scientific. This is a...
solaci -
Ir
Structural heart disease

Lotus Returns with New Strength and the FDA Approval to Compete with Sapien3 and CoreValve Evolut R

After reports of some serious adverse events with first-generation Lotus, the device was pulled off the market—but...
solaci -
Ir
Structural heart disease

Lotus Valve in Real Life Patients: the near total lack of leaks is its greatest strength

Even though the incidence of complications  in transcatheter aortic valve replacement (TAVR) have significantly decreased, there is one...
solaci -
Ir
Structural heart disease

REPRISE III: Need for Pacemaker and Paravalvular Leak with Lotus

A recent presentation at London Valves took a closer look at the REPRISE III trial as regards two...
solaci -
Ir
Structural heart disease

Lotus vs Sapien 3, different mechanisms with similar results

The new generation devices for transfemoral transcatheter aortic valve replacement have been optimized to improve valve position and...
solaci -
Ir
Structural heart disease

Lotus Valve performance related to pacemaker implantation in patients after TAVR

Courtesy of Dr. Agustín Vecchia. Paravalvular leak was once considered the greatest disadvantage of TAVR when compared to conventional surgery. Nowadays,...
solaci -
Ir
DAY 1

REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable Patients

The efficacy of transcatheter aortic valve replacement (TAVR) has been well-established. However, its limitations include suboptimal deployment...
solaci -
Ir
Live Cases and Live in a Box Cases

TAVR in Aortic Valve Stenosis with LOTUS

Operators: Alexandre Abizaid, Dimytri Siqueira, David Lebihan. Chairpersons: Martin Leon, José Eduardo Morais Rego Sousa. Panelists: José Armando Mangione,...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad